210 related articles for article (PubMed ID: 8108927)
1. High cure rate of invasive fungal infections in immunocompromised children using ambisome.
Ringdén O; Tollemar J; Dahllöf G; Tydén G
Transplant Proc; 1994 Feb; 26(1):175-7. PubMed ID: 8108927
[No Abstract] [Full Text] [Related]
2. Randomized double-blind study of liposomal amphotericin B (Ambisome) prophylaxis of invasive fungal infections in bone marrow transplant recipients.
Tollemar J; Ringdén O; Andersson S; Sundberg B; Ljungman P; Tydén G
Bone Marrow Transplant; 1993 Dec; 12(6):577-82. PubMed ID: 8136741
[TBL] [Abstract][Full Text] [Related]
3. Liposomal amphotericin B (AmBisome) therapy in invasive fungal infections. Evaluation of United Kingdom compassionate use data.
Ng TT; Denning DW
Arch Intern Med; 1995 May; 155(10):1093-8. PubMed ID: 7748054
[TBL] [Abstract][Full Text] [Related]
4. Liposomal amphotericin B (AmBisome) treatment of invasive fungal infections in immunocompromised children.
Ringdén O; Tollemar J
Mycoses; 1993; 36(5-6):187-92. PubMed ID: 8264715
[TBL] [Abstract][Full Text] [Related]
5. Prophylaxis and therapy using liposomal amphotericin B (AmBisome) for invasive fungal infections in children undergoing organ or allogeneic bone-marrow transplantation.
Ringdén O; Andström EE; Remberger M; Dahllöf G; Svahn BM; Tollemar J
Pediatr Transplant; 1997 Nov; 1(2):124-9. PubMed ID: 10084772
[TBL] [Abstract][Full Text] [Related]
6. Conventional vs. liposomal amphotericin B in immunosuppressed children.
Zoubek A; Emminger W; Emminger-Schmidmeier W; Peters C; Pracher E; Grois N; Gadner H
Pediatr Hematol Oncol; 1992; 9(2):187-90. PubMed ID: 1524992
[TBL] [Abstract][Full Text] [Related]
7. Prophylaxis with liposomal amphotericin B (AmBisome) prevents fungal infections in liver transplant recipients: long-term results of a randomized, placebo-controlled trial.
Tollemar J; Höckerstedt K; Ericzon BG; Jalanko H; Ringdén O
Transplant Proc; 1995 Feb; 27(1):1195-8. PubMed ID: 7878847
[No Abstract] [Full Text] [Related]
8. [Epidemiology and therapy of mycotic infections in immunocompromised host with special regard to the role of lipid formulations of amphotericin B].
Viscoli C; Castagnola E
Recenti Prog Med; 1999 Oct; 90(10):545-57. PubMed ID: 10592741
[TBL] [Abstract][Full Text] [Related]
9. Liposomal amphotericin B (AmBisome) efficacy in confirmed invasive aspergillosis and other filamentous fungal infections in immunocompromised hosts: a pooled analysis.
Cordonnier C; Bresnik M; Ebrahimi R
Mycoses; 2007 May; 50(3):205-9. PubMed ID: 17472618
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of amphotericin B encapsulated in liposomes (AmBisome) in the treatment of invasive fungal infections in immunocompromised patients.
Ringdén O; Meunier F; Tollemar J; Ricci P; Tura S; Kuse E; Viviani MA; Gorin NC; Klastersky J; Fenaux P
J Antimicrob Chemother; 1991 Oct; 28 Suppl B():73-82. PubMed ID: 1778894
[TBL] [Abstract][Full Text] [Related]
11. [Fungal infections in patients undergoing solid organ transplantation].
Muñoz P; Bouza E
Enferm Infecc Microbiol Clin; 1997 May; 15 Suppl 2():34-50. PubMed ID: 9312298
[No Abstract] [Full Text] [Related]
12. Voriconazole: new preparation. Invasive aspergillosis: benefits to be confirmed.
Prescrire Int; 2004 Feb; 13(69):13-6. PubMed ID: 15055210
[TBL] [Abstract][Full Text] [Related]
13. Management of immunocompromised patients with evidence of an invasive mycosis.
Walsh TJ
Hematol Oncol Clin North Am; 1993 Oct; 7(5):1003-26. PubMed ID: 8226563
[TBL] [Abstract][Full Text] [Related]
14. Liposomal amphotericin-B (AmBisome) for treatment of disseminated fungal infections in two infants of very low birth weight.
Lackner H; Schwinger W; Urban C; Müller W; Ritschel E; Reiterer F; Kuttnig-Haim M; Urlesberger B; Hauer C
Pediatrics; 1992 Jun; 89(6 Pt 2):1259-61. PubMed ID: 1594386
[No Abstract] [Full Text] [Related]
15. Safety of liposomal amphotericin B (AmBisome) in 187 transplant recipients treated with cyclosporin.
Ringdén O; Andström E; Remberger M; Svahn BM; Tollemar J
Bone Marrow Transplant; 1994; 14 Suppl 5():S10-4. PubMed ID: 7703925
[TBL] [Abstract][Full Text] [Related]
16. Risk of reactivation of a recent invasive fungal infection in patients with hematological malignancies undergoing further intensive chemo-radiotherapy. A single-center experience and review of the literature.
Martino R; Lopez R; Sureda A; Brunet S; Domingo-Albós A
Haematologica; 1997; 82(3):297-304. PubMed ID: 9234575
[TBL] [Abstract][Full Text] [Related]
17. Use of liposomal amphotericin B in bone marrow transplant.
Sastry PS; Parikh PM; Kulkarni PS; Bhagwat R; Gadade H
J Postgrad Med; 2005; 51 Suppl 1():S49-52. PubMed ID: 16519256
[TBL] [Abstract][Full Text] [Related]
18. Voriconazole in the management of invasive aspergillosis in two patients with acute myeloid leukemia undergoing stem cell transplantation.
Mattei D; Mordini N; Lo Nigro C; Ghirardo D; Ferrua MT; Osenda M; Gallamini A; Bacigalupo A; Viscoli C
Bone Marrow Transplant; 2002 Dec; 30(12):967-70. PubMed ID: 12476292
[TBL] [Abstract][Full Text] [Related]
19. Randomized trial of fluconazole versus low-dose amphotericin B in prophylaxis against fungal infections in patients undergoing hematopoietic stem cell transplantation.
Koh LP; Kurup A; Goh YT; Fook-Chong SM; Tan PH
Am J Hematol; 2002 Dec; 71(4):260-7. PubMed ID: 12447954
[TBL] [Abstract][Full Text] [Related]
20. Evolving concepts of prevention and treatment of invasive fungal infections in pediatric bone marrow transplant recipients.
Chanock SJ; Walsh TJ
Bone Marrow Transplant; 1996 Dec; 18 Suppl 3():S15-20. PubMed ID: 8971401
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
